243 related articles for article (PubMed ID: 14569643)
1. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Am J Alzheimers Dis Other Demen; 2003; 18(5):265-72. PubMed ID: 14569643
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine in vascular dementia.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
Expert Opin Pharmacother; 2004 Jun; 5(6):1399-410. PubMed ID: 15163283
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine in subcortical vascular dementia: an open 22-month study.
Moretti R; Torre P; Antonello RM; Cazzato G; Bava A
J Neurol Sci; 2002 Nov; 203-204():141-6. PubMed ID: 12417373
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study.
Moretti R; Torre P; Antonello RM; Cazzato G; Griggio S; Ukmar M; Bava A
Int J Clin Pract; 2004 Apr; 58(4):346-53. PubMed ID: 15161118
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine in vascular dementia.
Vincent S; Lane R
Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
7. [Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)].
Servello A; Andreozzi P; Bechini F; De Angelis R; Pontecorvo ML; Vulcano A; Cerra E; Vigliotta MT; Artini M; Selan L; Ettorre E
Minerva Med; 2014 Apr; 105(2):167-74. PubMed ID: 24727881
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine for subcortical vascular dementia.
Román GC
Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibition as a possible therapy for delirium in vascular dementia: a controlled, open 24-month study of 246 patients.
Moretti R; Torre P; Antonello RM; Cattaruzza T; Cazzato G
Am J Alzheimers Dis Other Demen; 2004; 19(6):333-9. PubMed ID: 15633941
[TBL] [Abstract][Full Text] [Related]
11. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.
Lojkowska W; Ryglewicz D; Jedrzejczak T; Minc S; Jakubowska T; Jarosz H; Bochynska A
J Neurol Sci; 2003 Dec; 216(1):119-26. PubMed ID: 14607313
[TBL] [Abstract][Full Text] [Related]
12. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Darreh-Shori T; Almkvist O; Guan ZZ; Garlind A; Strandberg B; Svensson AL; Soreq H; Hellström-Lindahl E; Nordberg A
Neurology; 2002 Aug; 59(4):563-72. PubMed ID: 12196650
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up.
Moretti R; Torre P; Antonello RM; Cazzato G
Eur J Neurol; 2001 Jul; 8(4):361-2. PubMed ID: 11422435
[No Abstract] [Full Text] [Related]
15. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
16. Effect of treatment with the cholinesterase inhibitor rivastigmine on vesicular acetylcholine transporter and choline acetyltransferase in rat brain.
Tayebati SK; Di Tullio MA; Amenta F
Clin Exp Hypertens; 2004 May; 26(4):363-73. PubMed ID: 15195690
[TBL] [Abstract][Full Text] [Related]
17. Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia.
Moretti R; Torre P; Antonello RM; Cazzato G; Pizzolato G
Am J Alzheimers Dis Other Demen; 2008; 23(2):167-76. PubMed ID: 18184948
[TBL] [Abstract][Full Text] [Related]
18. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Bullock R; Cameron A
Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Rösler M
Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
[TBL] [Abstract][Full Text] [Related]
20. Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman.
Alagiakrishnan K; Sclater A; Robertson D
J Am Geriatr Soc; 2003 Sep; 51(9):1326. PubMed ID: 12919253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
